BridgeBio Pharma, Inc. Common Stock (BBIO)
Health Care – PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 839
- Market Cap
- $13.6B
About BridgeBio Pharma, Inc. Common Stock
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
BridgeBio Pharma, Inc. Common Stock stock analysis, sentiment tracking, and market intelligence on SentiSense.